Payment overview · 2025
General Payments
$807.58
36 reported records · 14 companies
Healthcare provider profile · identity verified
David S. Haacker, MD
Allopathic & Osteopathic Physicians|Internal Medicine · WEST ORANGE, NJ · NPI 1902879000
Verified facts
What the public records show
CMS Open Payments records show David S. Haacker, MD received $807.58 in general payments during 2025 across 36 reported records.
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) accounted for 26.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ISENTRESS as an associated drug or biological on 37 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Isentress by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $210.21 | 26.0% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $123.17 | 15.2% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $102.48 | 12.7% | 5 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $96.30 | 11.9% | 6 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $58.44 | 7.2% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $45.90 | 5.7% | 2 | 2025 |
| BridgeBio Pharma, Inc. | Unresolved — no canonical attribution shown | $33.71 | 4.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $31.56 | 3.9% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$23.37 | 2.9% | 1 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $19.64 | 2.4% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.89 | 2.2% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $17.01 | 2.1% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.42 | 1.8% | 1 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $13.48 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $807.58 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $210.21 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $123.17 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $102.48 | 5 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $96.30 | 6 | 2025 |
Source payment records
|
|||||
| CDS - MCT/CEM Monitoring Normalized: cds mct cem monitoring |
Device | Boston Scientific Corporation | $58.44 | 3 | 2025 |
Source payment records
|
|||||
| Attruby Normalized: attruby |
Drug | BridgeBio Pharma, Inc. | $33.71 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $31.56 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $31.56 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $28.66 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $23.37 | 1 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $19.64 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $17.89 | 1 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $14.42 | 1 | 2025 |
Source payment records
|
|||||
| Hillrom - Cardiac Ambulatory Monitor Normalized: hillrom cardiac ambulatory monitor |
Device | Baxter Healthcare | $13.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 52 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | ISENTRESS open payments reported associated product |
CMS Open Payments — General Payments 37 supporting records · 24 recipient NPIs · example record 1238003286 |
Isentress · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 513 | 105 |
| Amlodipine Besylate | Amlodipine Besylate | 417 | 83 |
| Levothyroxine Sodium | Levothyroxine Sodium | 378 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 290 | 52 |
| Escitalopram Oxalate | Escitalopram Oxalate | 247 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 246 | 34 |
| Divalproex Sodium | Divalproex Sodium | 244 | 29 |
| Donepezil Hcl | Donepezil Hcl | 239 | 30 |
| Metformin Hcl | Metformin Hcl | 235 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 231 | 51 |
| Lisinopril | Lisinopril | 188 | 29 |
| Eliquis | Apixaban | 182 | 24 |
| Memantine Hcl | Memantine Hcl | 181 | 22 |
| Furosemide | Furosemide | 178 | 38 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 170 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 151 | 26 |
| Mirtazapine | Mirtazapine | 148 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 136 | 19 |
| Trazodone Hcl | Trazodone Hcl | 117 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 113 | 29 |
| Carvedilol | Carvedilol | 111 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 110 | 22 |
| Gabapentin | Gabapentin | 104 | 22 |
| Allopurinol | Allopurinol | 93 | 23 |
| Januvia | Sitagliptin Phosphate | 84 | 11 |
| Famotidine | Famotidine | 81 | 19 |
| Sertraline Hcl | Sertraline Hcl | 80 | 19 |
| Xarelto | Rivaroxaban | 80 | 11 |
| Omeprazole | Omeprazole | 78 | 13 |
| Potassium Chloride | Potassium Chloride | 76 | 14 |
| Ezetimibe | Ezetimibe | 74 | 16 |
| Losartan Potassium | Losartan Potassium | 74 | 20 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 74 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 69 | suppressed |
| Entresto | Sacubitril/Valsartan | 68 | suppressed |
| Simvastatin | Simvastatin | 64 | 12 |
| Alprazolam | Alprazolam | 62 | 22 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 62 | 14 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 61 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 60 | suppressed |
| Valsartan | Valsartan | 60 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 60 | 11 |
| Metformin Hcl Er | Metformin Hcl | 58 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 57 | 13 |
| Levetiracetam | Levetiracetam | 57 | suppressed |
| Ozempic | Semaglutide | 52 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 52 | 12 |
| Risperidone | Risperidone | 52 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 48 | suppressed |
| Lactulose | Lactulose | 45 | suppressed |
| Lorazepam | Lorazepam | 45 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 43 | 14 |
| Clonazepam | Clonazepam | 43 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 43 | suppressed |
| Atenolol | Atenolol | 41 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Ramipril | Ramipril | 41 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 38 | 15 |
| Paliperidone Er | Paliperidone | 38 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 34 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 25 |
| Farxiga | Dapagliflozin Propanediol | 33 | suppressed |
| Baclofen | Baclofen | 30 | suppressed |
| Ibuprofen | Ibuprofen | 30 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 27 | suppressed |
| Jardiance | Empagliflozin | 27 | suppressed |
| Latanoprost | Latanoprost | 27 | suppressed |
| Mupirocin | Mupirocin | 27 | 14 |
| Alendronate Sodium | Alendronate Sodium | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Meloxicam | Meloxicam | 26 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | 17 |
| Finasteride | Finasteride | 25 | suppressed |
| Methimazole | Methimazole | 25 | suppressed |
| Olanzapine | Olanzapine | 25 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 25 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 25 | suppressed |
| Spironolactone | Spironolactone | 25 | suppressed |
| Glimepiride | Glimepiride | 24 | suppressed |
| Insulin Lispro | Insulin Lispro | 24 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 24 | 13 |
| Dutasteride | Dutasteride | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 23 | suppressed |
| Irbesartan | Irbesartan | 23 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 21 | suppressed |
| Budesonide | Budesonide | 21 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 17 |
| Methenamine Hippurate | Methenamine Hippurate | 20 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Ingrezza | Valbenazine Tosylate | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 14 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 13 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Balsalazide Disodium | Balsalazide Disodium | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Isentress | Raltegravir Potassium | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Entecavir | Entecavir | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Lyvispah | Baclofen | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $807.58 · 36 records | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | AREXVY, Attruby, Barostim Neo System, CDS - MCT/CEM Monitoring, Cologuard Collection Kit, Hillrom - Cardiac Ambulatory Monitor, Kerendia, LifeVest, MINIMED 780G, ONPATTRO, Ozempic, REXULTI, SHINGRIX, VERQUVO | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Merck Sharp & Dohme LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error